ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
2 hedge funds and large institutions have $4.64K invested in ELITE PHARMACEUTICAL in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
71% less capital invested
Capital invested by funds: $15.9K → $4.64K (-$11.3K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFG
Citizens Financial Group
Providence,
Rhode Island
|
-$5K |
ELI Hedge Fund Activity: Q2 2019 in Review
2 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2019, worth a combined $4.64K — down 71% from $15.9K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ELI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Citizens Financial Group, exiting entirely with an estimated $5K sold.
- 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2019, down from 3 in Q1 2019.
- Funds reported $4.64K of ELITE PHARMACEUTICAL stock for Q2 2019, down 71% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q2 2019 and 1 closed out, a net change of -1 holder.
- The largest ELITE PHARMACEUTICAL seller in Q2 2019 was Citizens Financial Group, an estimated $5K sold.
Based on aggregated 13F filings for Q2 2019.